Patents Examined by Sam Rosen
  • Patent number: 5274300
    Abstract: This invention relates to a method for the production of (2R,3S)-3-(4-methoxyphenyl)glycidic acids and esters thereof, which are synthetic intermediates for the production of the calcium antagonist diltiazem. The method involves the stereoselective enzymatic ester hydrolysis of racemic trans-3-(4-methoxyphenyl)glycidic acid ester to yield the resolved 2R,3S compound as the ester. Membrane reactor methods and apparatus for the conduct of this enzymatic resolution process are also disclosed herein, as is the use of bisulfite anion in the aqueous reaction phase as a means of minimizing the inhibitory effect of an aldehyde reaction by-product on the reaction's progress.
    Type: Grant
    Filed: February 10, 1989
    Date of Patent: December 28, 1993
    Assignee: Sepracor, Inc.
    Inventors: David R. Dodds, Jorge L. Lopez
  • Patent number: 5272059
    Abstract: The invention concerns a process for the preparation of hybridoma cells which secrete monoclonal antibodies specific for hirudin, the hybridoma cells themselves, the monoclonal antibodies specific for hirudin secreted by these hybridoma cells, derivatives thereof, and a process for the preparation of said antibodies and derivatives. These monoclonal anti-hirudin antibodies and their derivatives are useful for the determination of hirudin and as an antidote to hirudin. The invention also concerns test kits and pharmaceutical compositions comprising said monoclonal antibodies and/or derivatives.
    Type: Grant
    Filed: July 27, 1992
    Date of Patent: December 21, 1993
    Assignee: Ciba-Geigy Corporation
    Inventors: Jean-Marc Schlaeppi, Dietmar G. Braun
  • Patent number: 5270206
    Abstract: Process for the pancreatic lipase mediated transesterification method for the optical resolution of endo-norborneol; derived optically active 5-(3-(exo-bicyclo[2.2.1]hept-2-yloxy)-4-methoxyphenyl)-3,4,5,6-tetrahydrop yrimidin-2(1H)-ones; and stepwise process and intermediate therefor.
    Type: Grant
    Filed: May 8, 1992
    Date of Patent: December 14, 1993
    Assignee: Pfizer Inc.
    Inventor: Nicholas A. Saccomano
  • Patent number: 5270168
    Abstract: The present invention provides methods for the diagnosis of non-healing ulcers in humans. Provided are methods for detecting the presence of non-healing ulcers by assaying for certain cell adhesion-related proteins or their degradation products in ulcer exudate. The methods of the present invention are useful as an initial, quick and inexpensive screening process for a condition which is often misdiagnosed. It has been discovered that in non-healing ulcers there appear to be proteases which degrade cell adhesion-related proteins, e.g., fibronectin and vitronectin. Protein separation techniques, such as electrophoresis, may be used in combination with immunoassay techniques to isolate and identify these degradation products, as well as the cell adhesion-related proteins themselves.
    Type: Grant
    Filed: November 21, 1991
    Date of Patent: December 14, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventor: Frederick Grinnell
  • Patent number: 5266464
    Abstract: Inhibitors and activators of a protein whose expression affects a phenotypic characteristic of the cell, especially a cultural or morphological characteristic, are identified by their more pronounced effect on cells producing higher, usually non-naturally occurring, levels of the protein, than on cells producing little or none of the protein. In a preferred assay, the effect is observable with the naked eye.By this method, tamoxifen is identified as an inhibitor of PKC activity in cell culture.
    Type: Grant
    Filed: August 10, 1989
    Date of Patent: November 30, 1993
    Assignee: ICT Pharmaceuticals, Inc.
    Inventor: Gerard Housey
  • Patent number: 5266461
    Abstract: The present invention provides a reagent for determining (1.fwdarw.3)-.beta.-D-glucan comprising limulus amebocyte lysate and an antibody to an endotoxin-sensitive factor, or comprising endotoxin-sensitive factor-free lysate, which enables highly sensitive determination of mycotic (1.fwdarw.3)-.beta.-D-glucan present in biological samples such as blood, urine and cerebrospinal fluid without any interference of endotoxin. Thus, deep mycosis difficult to detect can be rapidly diagnosed with a good reproducibility. Accordingly, the present invention greatly contributes to the clinical diagnosis. specifically the assay is aided by the removal of intefering endotoxin sentitive factor.
    Type: Grant
    Filed: February 20, 1992
    Date of Patent: November 30, 1993
    Assignee: Seikagaku Corporation
    Inventor: Shigenori Tanaka
  • Patent number: 5266499
    Abstract: An apparatus and method for detecting antibodies specific to non-protein antigens. The apparatus is an immunological plate containing a plurality of plastic projections coated with a non-protein material. Assays utilizing the plate are capable of stabilizing the non-protein antigens with detection levels for antibodies specific to the antigens on a nanogram level. A screening assay with the apparatus allows for early detection of exposure to non-protein materials. Specifically metallic elements are detected.
    Type: Grant
    Filed: February 25, 1992
    Date of Patent: November 30, 1993
    Assignee: The United States of America as represented by the United States Department of Energy
    Inventors: Charles W. Barrick, Sara M. Clarke, Carl W. Nordin
  • Patent number: 5264370
    Abstract: Methods for the diagnosis of diseases that result in the release of fragments of basement membrane, including fragments, intact molecules and/or complexes of basement membrane components, are disclosed. Detection of basement membrane fragments, intact molecules and/or complexes in a biological fluid by the immunological and physicochemical methods of the present invention allows the diagnosis of a variety of diseases, including cancers, collagen degenerative diseases, and hepatitis. Suitable biological fluids include urine, serum, synovial fluid, and cerebrospinal fluid.
    Type: Grant
    Filed: June 26, 1991
    Date of Patent: November 23, 1993
    Assignee: Bainbridge Laboratories, Inc.
    Inventors: Morgan V. Aken, Stefan L. Paskell
  • Patent number: 5262302
    Abstract: A method and apparatus for automatically and rapidly, retrieving, counting and/or analyzing at least one selected white blood cell population and/or subset thereof of an aged whole blood sample or portion thereof. A volume of a biological sample containing the white blood cells is prepared and at least one reactant specific or preferential at least to some selected biological cells is introduced thereto and rapidly mixed for a short period of time. The total white blood cell populations and lymphocyte population are first electronically counted and then the neutrophil population including the aged neutrophil population is removed from the same or a second sample portion. The opacity and/or volume parameter of the cells then can be modified and the mixture then again is counted and analyzed in one or more steps to obtain the desired white blood cell population analysis.
    Type: Grant
    Filed: May 3, 1991
    Date of Patent: November 16, 1993
    Assignee: Coulter Corporation
    Inventor: Thomas Russell
  • Patent number: 5260188
    Abstract: A method for determining the suitability of an organ for transplant by performing one or more tests on the endothelial cells lining the blood vessels in the organ prior to the transplant operation. Specifically hyaluronic acid is used as the measure to determine liver transplant effectiveness.
    Type: Grant
    Filed: May 19, 1992
    Date of Patent: November 9, 1993
    Assignee: University of Pittsburgh of the Commonwealth System of Higher Education
    Inventor: Prakash N. Rao
  • Patent number: 5258312
    Abstract: A method for diagnosing a patient with an autoimmune disease comprising assaying a blood sample from a patient for increased levels of the carbohydrate moieties of one or more proteins, said increased level of one or more of said proteins indicating the presence of an autoimmune disease.
    Type: Grant
    Filed: June 24, 1991
    Date of Patent: November 2, 1993
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A
    Inventors: Bruno Silvestrini, Yan Cheng
  • Patent number: 5256538
    Abstract: The present invention relates to a highly sensitive diagnostic/prediagnostic test to identify persons at risk of a thrombotic event. Thrombotic events include myocardial infarction, deep venous thrombosis, pulmonary embolism, thromboembolic stroke pulmonary embolism deep venous and cardiovascular disease. The test is based on the early detection of elevated levels of resting platelet surface thrombospondin. The present invention also includes methods of determining the presence of thrombospondin on the surface TSP receptors of resting platelets in a biological sample. An anti-thrombospondin monoclonal antibody which is specific for thrombospondin on resting platelets is also disclosed. A diagnostic test in the form of a test kit for the determination of thrombospondin levels in a patient sample, and also for the prediagnosis of persons at risk for thrombotic events, is also described.
    Type: Grant
    Filed: March 8, 1991
    Date of Patent: October 26, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: Martha L. Aiken, Richard G. Painter
  • Patent number: 5256539
    Abstract: A method for detecting the presence of infertility in mammalian male animals based upon failure of sperm to undergo successful capacitation. Sperm samples are given the opportunity to undergo capacitation and subsequently contacted with antibodies to fibronectin. Binding levels indicate the degree of capacitation and consequently the presence of infertility.
    Type: Grant
    Filed: August 1, 1991
    Date of Patent: October 26, 1993
    Assignee: The Research Foundation of State University of New York
    Inventor: Richard A. Bronson
  • Patent number: 5256411
    Abstract: A method for treating an immune system disorder in a human by administering to the human a therapeutically effective amount of an active substance selected from the group consisting of PP14, derivatives of PP14, muteins of PP14, fragments of PP14, and subunits of PP14, to alleviate the immune system disorder.
    Type: Grant
    Filed: June 28, 1991
    Date of Patent: October 26, 1993
    Assignee: Intermune Life Sciences, Inc.
    Inventors: Anthony E. Bolton, Alan Drizen
  • Patent number: 5254339
    Abstract: A process is provided for preparing an immunogenic complex containing antigenic proteins and peptides with hydrophobic domains, whereby proteins or peptides from viruses, mycoplasmas, bacteria, parasites, animal cells with hydrophobic domains are mixed with one or more solubilizing agents, whereby complexes are formed between proteins or peptides and the solubilizing agent, where after the proteins or peptides are separated from solubilizing agent in the presence of, or are separated from, the solubilizing agent and directly transferred to a glycoside solution, containing one or more glycosides with hydrophobic and hydrophilic domains in a concentration of at least the critical micellar concentration, thereby forming a protein complex which is isolated and purified, characterized in that lipids are added before the complex is isolated and purified.
    Type: Grant
    Filed: June 1, 1987
    Date of Patent: October 19, 1993
    Inventor: Bror Morein
  • Patent number: 5254329
    Abstract: A method for the visualization of serotonergic cells in the dorsal raphe of living nonhuman vertebrates by pretreatment with L-tryptophan significantly less than one hour prior to sacrifice reveals numerous structures and cell types hitherto unidentified when combined with immunocytochemistry, immunofluorescence, or serotonin tagged autoradiography in the light microscope.
    Type: Grant
    Filed: March 11, 1991
    Date of Patent: October 19, 1993
    Inventor: Melvyn H. Keiner
  • Patent number: 5252489
    Abstract: The present invention relates to a method for detecting fetal Down syndrome (Trisomy 21), trisomy 13, trisomy 18 and other chromosomal anomalies during prenatal screening by analyzing a dried blood sample from a pregnant woman. More particularly the present invention relates to a method for improving detection efficiency in screening for the anomalies by measuring the amount of the free beta human chorionic gonadotropin (HCG) and nicked or fragmented or aberrant forms of free beta (HCG), all of which are referenced throughout this application as free beta (HCG) in dried blood samples from pregnant women.
    Type: Grant
    Filed: August 7, 1992
    Date of Patent: October 12, 1993
    Inventor: James N. Macri
  • Patent number: 5250413
    Abstract: A sublethal assay is conducted to determine the presence of a stressor in the environment. An organism exposed to the environment is assayed for the presence of shock proteins, produced in response to environmental stress. The amount of stress protein can be quantified to give an indication of the concentration or amount of stressor, and qualified, by assay for various shock proteins, to give an indication as to the nature of the stressor. The health of an organism may be determined by the assay.
    Type: Grant
    Filed: June 30, 1992
    Date of Patent: October 5, 1993
    Assignee: The University of Maryland
    Inventor: Brian P. Bradley
  • Patent number: 5250303
    Abstract: This invention provides an improved method for prolonging the shelf life of transfusible red blood cells by decreasing the effective osmolality of the suspending solution and increasing the intracellular pH of the cells prior to storage thereof. This invention also provides methods whereby the intracellular pH may be increased. These methods include collecting the cells in an anticoagulant at pH 7.0 or higher and/or washing, diluting or resuspending the cells prior to storage thereof in a biologically compatible buffered solution that contains at least one non-penetrating or substantially non-penetrating anion or non-electrolyte and is substantially free of chloride ions.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: October 5, 1993
    Assignee: The American National Red Cross
    Inventors: Harold T. Meryman, Marne Hornblower, Ralph Syring
  • Patent number: 5248593
    Abstract: The present invention provides an immunological process for the determination of the luteinizing hormone (LH), wherein at least one monoclonal antibody is used which is directed against LH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.The present invention also provides a reagent for the determination of the luteinizing hormone, wherein it contains at least one monoclonal antibody which is directed against LH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.Furthermore, the present invention provides a monoclonal antibody against the luteinizing hormone and a process and a hybridoma cell line for producing it.
    Type: Grant
    Filed: June 29, 1992
    Date of Patent: September 28, 1993
    Assignee: Boehringer Mannheim GmbH
    Inventors: Christa Hubner-Parajsz, Hartmut Schetters, Helmut Lenz, Klaus Erler